Highlights Acelyrin, Inc.

Equities

SLRN

US00445A1007

Market Closed - Nasdaq Other stock markets 20:59:51 29/05/2024 BST			5-day change	1st Jan Change
4.075 ^USD	+0.62%		-9.85%	-45.38%

05-22	HC Wainwright Adjusts Price Target on ACELYRIN to $18 From $16, Maintains Buy Rating	MT
05-09	Acelyrin, Inc. Announces Ron Oyston to Step Down as Chief People Officer, Effective August 15, 2024	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Acelyrin, Inc. Announces CEO Changes	05-09	CI
Acelyrin, Inc. Announces Leadership Transition	05-09	CI
Acelyrin, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
North American Morning Briefing : Stocks Struggle After New Records	03-22	DJ
Sector Update: Health Care Stocks Ease Late Afternoon	03-20	MT
Sector Update: Health Care	03-20	MT
Acelyrin Shares Rise After Lonigutamab Shows Clinical Responses in Thyroid Eye Disease Trial	03-20	MT
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-Of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease	03-20	CI
Acelyrin, Inc. Announces Positive Top-Line Results from Its Global Phase 2B/3 Clinical Trial of Izokibep in Psoriatic Arthritis	03-11	CI
Acelyrin, Inc. Announces Long-Term 32-Week Data from the Phase 2B Trial of Izokibep in Hidradenitis Suppurativa	03-11	CI
ACELYRIN Flags 'Clinical Execution Errors' in Hidradenitis Suppurativa Trials Involving Contract Research Organization	11-28	MT
North American Morning Briefing : November Rally Pauses Ahead of This Week's PCE Report	11-28	DJ
ACELYRIN Flags 'Clinical Execution Errors' in Hidradenitis Suppurativa Trials Involving Contract Research Organization	11-27	MT
Acelyrin, Inc. Provides Update on Izokibep Clinical Development Program	11-27	CI
Acelyrin, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Acelyrin Shares Plunge After Izokibep Trial Misses Primary Endpoint	12/09/23	MT
Acelyrin tumbles after skin disease drug fails key trial	12/09/23	RE
Acelyrin Results From Izokibep Trial for Hidradenitis Suppurativa Fail to Meet Primary Endpoint; Shares Sink Premarket	12/09/23	MT
Acelyrin Topline Results From Izokibep Trial for Hidradenitis Suppurativa Fail to Meet Primary Endpoint; Shares Plunge	11/09/23	MT
Acelyrin Shares Rise Tuesday After Reporting Narrower Q2 Loss	15/08/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Acelyrin, Inc.

Equities

SLRN

US00445A1007

Highlights

Filters